Whittier Trust Co. Sells 348 Shares of Solventum Corporation $SOLV

Whittier Trust Co. trimmed its holdings in shares of Solventum Corporation (NYSE:SOLV) by 8.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,906 shares of the company’s stock after selling 348 shares during the period. Whittier Trust Co.’s holdings in Solventum were worth $296,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SOLV. Rossby Financial LCC purchased a new stake in Solventum during the first quarter valued at about $25,000. Strengthening Families & Communities LLC boosted its position in Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares during the period. Barrett & Company Inc. boosted its position in Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after buying an additional 268 shares during the period. Hara Capital LLC purchased a new stake in Solventum during the first quarter valued at about $38,000. Finally, Smartleaf Asset Management LLC boosted its position in Solventum by 193.4% during the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after buying an additional 352 shares during the period.

Wall Street Analyst Weigh In

Several research firms have issued reports on SOLV. Weiss Ratings restated a “hold (c-)” rating on shares of Solventum in a research report on Wednesday, October 8th. Piper Sandler restated an “overweight” rating and set a $94.00 price target (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. UBS Group began coverage on shares of Solventum in a research report on Wednesday, October 1st. They set a “neutral” rating and a $77.00 price target for the company. Finally, Jefferies Financial Group assumed coverage on shares of Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $84.89.

Solventum Trading Down 0.6%

SOLV opened at $72.30 on Friday. The business has a 50 day simple moving average of $72.62 and a two-hundred day simple moving average of $72.07. The firm has a market capitalization of $12.54 billion, a price-to-earnings ratio of 33.47, a PEG ratio of 2.96 and a beta of 0.50. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.Solventum’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.